Overall rank by patents
#24,699
of 50,000 tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 13 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).
The verdict
According to USPTO PatentsView, Leukocare ranks #24,699 of 50,000 tracked US assignees by granted-patent volume, with 11 patents across 13 technology areas.
USPTO PatentsView assignee plate
Corpus R24699 · Foreign Corporation #24,699 · 11 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-FLAT · BOOK-FULL
Nearest grant-volume peer: Lambda:4 Entwicklungen Gmbh (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Leukocare · this assignee
33 score
3D Lighting Innovati… · lowest
7 score
What this shows Leukocare's Innovation Score is 33.1/100 (top 57% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Leukocare Ag is a focused PatentsView assignee: 13 CPC subclasses with 63.6% of grants classified under C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). Peak complete grant year is 2019 (2 grants) versus a trough of 1 in 2016. By volume, Leukocare sits between Lambda:4 Entwicklungen Gmbh and Licentia Group Limited.
Leukocare Ag shows 2 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Lambda:4 Entwicklungen GmbH
11 patents
Laminated Film LLC
11 patents
Lehigh Defense, LLC
11 patents
Lemi Technology, LLC
11 patents
Libert Lift Solutions, LLC
11 patents
Liberty Evans, LLC
11 patents
Liberty Sport, Inc.
11 patents
Licentia Group Limited
11 patents
Leukocare AG
11 patents
What this shows Leukocare holds 11 patents at rank #24,704, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #24,704 in granted patent volume.
Other assignees with the most granted patents in Leukocare's primary technology class.
Leukocare's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
33 Top 57% higher than 43% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 9.1% |
| 2017 | 1 | 9.1% |
| 2018 | 1 | 9.1% |
| 2019 | 2 | 18.2% |
| 2020 | 1 | 9.1% |
| 2021 | 2 | 18.2% |
| 2022 | 1 | 9.1% |
| 2023 | 1 | 9.1% |
| 2025partial year | 1 | 9.1% |
Top 13 of 13 technology areas
Overall rank by patents
#24,699
of 50,000 tracked assignees
33.1 out of 100
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.